Transcriptional splice variants of CD40 and its prognostic value in breast cancer
Yıl: 2020 Cilt: 44 Sayı: 2 Sayfa Aralığı: 73 - 81 Metin Dili: İngilizce DOI: 10.3906/biy-1912-21 İndeks Tarihi: 30-04-2020
Transcriptional splice variants of CD40 and its prognostic value in breast cancer
Öz: CD40 is an important tumor necrosis factor receptor (TNFR) family protein for the development of antitumor responseagainst cancer cells, apart from its role in the regulation of the immune system as a costimulatory molecule. It is broadly expressed onthe surface of immune cells and in diverse cancer types, including breast cancer. Here, we analyzed both CD40/CD40 ligand expressionin breast cancer cells and tissues using public data sets and overall survival analysis in ungrouped breast cancer patients, as well asin the triple-negative breast cancer subtype. We detected CD40 gene expression along with its 3 different splice variants (variants1–3), predominantly in the triple-negative subgroup of breast cancer cell lines. The results of the overall survival analysis showed thathigh CD40 gene expression, particularly in the triple-negative subgroup of breast cancer patients, is associated with better survival. Inaddition to the transcriptional levels of CD40 splice variants, investigation of protein levels of these variants will allow the categorizationof breast cancer cells and reveal their potential as an immunotherapeutic target.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Ara A, Ahmed KA, Xiang J (2018). Multiple effects of CD40–CD40L axis in immunity against infection and cancer. ImmunoTargets and Therapy 7: 55-61.
- Argiriadi MA, Benatuil L, Dubrovska I, Egan DA, Gao L et al. (2019). CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Molecular and Cell Biology 20: 29.
- Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
- Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G et al. (2005). Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 24: 7913- 7923.
- Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S et al. (2019). Cold tumors: a therapeutic challenge for ımmunotherapy. Frontiers in Immunology 10: 168.
- Dong L, Wang S, Chen M, Li H, Bi W (2008). The activation of macrophage and upregulation of CD40 costimulatory molecule in lipopolysaccharide-induced acute lung injury. Journal of Biomedicine and Biotechnology 2008: 852571.
- Esteva FJ, Wang J, Lin F, Mejia JA, Yan K et al. (2007). CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Research 9: R87.
- Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C et al. (2009). Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clinical Cancer Research 15: 1317-1325.
- Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J et al. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Research and Treatment 123: 725-731.
- Kim H, Kim Y, Bae S, Kong JM, Choi J et al. (2015). Direct ınteraction of CD40 on tumor cells with CD40L on T cells ıncreases the proliferation of tumor cells by enhancing TGF-beta production and Th17 differentiation. PLoS One 10: e0125742.
- Li R, Chen WC, Pang XQ, Hua C, Li L et al. (2009). Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. International Journal of Molecular Sciences 10: 3900-3917.
- Loskog AS, Eliopoulos AG (2009). The Janus faces of CD40 in cancer. Seminars in Immunology 21: 301-307.
- Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T (2018). Breast cancer immunotherapy: an update. Breast Cancer: Basic and Clinical Research 12. doi: 10.1177/1178223418774802
- Matsumura Y, Hiraoka K, Ishikawa K, Shoji Y, Noji T et al. (2016). CD40 Expression in human esophageal squamous cell carcinoma ıs associated with tumor progression and lymph node metastasis. Anticancer Research 36: 4467-4475.
- Mu CY, Qin PX, Qu QX, Chen C, Huang JA (2015). Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer: A potential marker of prognosis. Chronic Diseases and Translational Medicine 1: 36-41.
- Ottaiano A, De Chiara A, Perrone F, Botti G, Fazioli F et al. (2004). Prognostic value of CD40 in adult soft tissue sarcomas. Clinical Cancer Research 10: 2824-2831.
- Pearson LL, Castle BE, Kehry MR (2001). CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogenactivated protein kinase signaling pathways. International Immunology 13: 273-283.
- Piechutta M, Berghoff AS (2019). New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5). ESMO Open 4: e000510.
- Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN (2005). LPS induces CD40 gene expression through the activation of NFkappaB and STAT-1alpha in macrophages and microglia. Blood 106: 3114-3122.
- Rydstrom K, Linderoth J, Nyman H, Ehinger M, Joost P et al. (2010). CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia&Lymphoma 51: 1643-1648.
- Slobodova Z, Ehrmann J, Krejci V, Zapletalova J, Melichar B (2011). Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. Neoplasma 58: 189-197.
- Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H (2001). Regulation of CD40 function by its isoforms generated through alternative splicing. Proceedings of the National Academy of Sciences of the United States of America 98: 1751-1756.
- Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G et al. (2001). Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clinical Cancer Research 7: 691-703.
- Tong AW, Stone MJ (2003). Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Therapy 10: 1-13.
- Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL et al. (2009). Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America 106: 19455-19460.
- Weiss JM, Gregory Alvord W, Quinones OA, Stauffer JK, Wiltrout RH (2014). CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival. Human Immunology 75: 614-620.
- Werner JM, Kuhl S, Ulrich K, Krischek B, Stavrinou P et al. (2019). Expression of CD40 correlates negatively with overall and progression-free survival of low- and high-grade gliomas. World Neurosurgery 130: e17-e25.
- Wu W, Alexis NE, Bromberg PA, Jaspers I, Peden DB (2009). Mechanisms of LPS-induced CD40 expression in human peripheral blood monocytic cells. Biochemical and Biophysical Research Communications 379: 573-577.
- Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW (1998). CD40 and epithelial cells: across the great divide. Immunology Today 19: 502-506.
- Yu S, Kim T, Yoo KH, Kang K (2017). The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer. Biochemical Biophysical Research Communications 486: 752-758.
| APA | UNVER N, YÖYEN ERMİŞ D, WEBER B, ESENDAĞLI G (2020). Transcriptional splice variants of CD40 and its prognostic value in breast cancer. , 73 - 81. 10.3906/biy-1912-21 |
| Chicago | UNVER Nese,YÖYEN ERMİŞ Diğdem,WEBER Bahar Zehra,ESENDAĞLI Güneş Transcriptional splice variants of CD40 and its prognostic value in breast cancer. (2020): 73 - 81. 10.3906/biy-1912-21 |
| MLA | UNVER Nese,YÖYEN ERMİŞ Diğdem,WEBER Bahar Zehra,ESENDAĞLI Güneş Transcriptional splice variants of CD40 and its prognostic value in breast cancer. , 2020, ss.73 - 81. 10.3906/biy-1912-21 |
| AMA | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G Transcriptional splice variants of CD40 and its prognostic value in breast cancer. . 2020; 73 - 81. 10.3906/biy-1912-21 |
| Vancouver | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G Transcriptional splice variants of CD40 and its prognostic value in breast cancer. . 2020; 73 - 81. 10.3906/biy-1912-21 |
| IEEE | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G "Transcriptional splice variants of CD40 and its prognostic value in breast cancer." , ss.73 - 81, 2020. 10.3906/biy-1912-21 |
| ISNAD | UNVER, Nese vd. "Transcriptional splice variants of CD40 and its prognostic value in breast cancer". (2020), 73-81. https://doi.org/10.3906/biy-1912-21 |
| APA | UNVER N, YÖYEN ERMİŞ D, WEBER B, ESENDAĞLI G (2020). Transcriptional splice variants of CD40 and its prognostic value in breast cancer. Turkish Journal of Biology, 44(2), 73 - 81. 10.3906/biy-1912-21 |
| Chicago | UNVER Nese,YÖYEN ERMİŞ Diğdem,WEBER Bahar Zehra,ESENDAĞLI Güneş Transcriptional splice variants of CD40 and its prognostic value in breast cancer. Turkish Journal of Biology 44, no.2 (2020): 73 - 81. 10.3906/biy-1912-21 |
| MLA | UNVER Nese,YÖYEN ERMİŞ Diğdem,WEBER Bahar Zehra,ESENDAĞLI Güneş Transcriptional splice variants of CD40 and its prognostic value in breast cancer. Turkish Journal of Biology, vol.44, no.2, 2020, ss.73 - 81. 10.3906/biy-1912-21 |
| AMA | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G Transcriptional splice variants of CD40 and its prognostic value in breast cancer. Turkish Journal of Biology. 2020; 44(2): 73 - 81. 10.3906/biy-1912-21 |
| Vancouver | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G Transcriptional splice variants of CD40 and its prognostic value in breast cancer. Turkish Journal of Biology. 2020; 44(2): 73 - 81. 10.3906/biy-1912-21 |
| IEEE | UNVER N,YÖYEN ERMİŞ D,WEBER B,ESENDAĞLI G "Transcriptional splice variants of CD40 and its prognostic value in breast cancer." Turkish Journal of Biology, 44, ss.73 - 81, 2020. 10.3906/biy-1912-21 |
| ISNAD | UNVER, Nese vd. "Transcriptional splice variants of CD40 and its prognostic value in breast cancer". Turkish Journal of Biology 44/2 (2020), 73-81. https://doi.org/10.3906/biy-1912-21 |
